The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
Recognizing the need for responsible and inclusive AI development, a new global initiative the AI…
Microsoft has joined hands with Singapore-based telecom infrastructure company Lightstorm to develop the new undersea…
In 2027, the International Booker Prize will officially to be renamed as the Bukhman International…
When we think about parenting in the animal kingdom, mothers usually receives the most of…
Japan's political leadership has seen various transitions from the Meiji era to the present day.…
India and Japan strengthened their Special Strategic and Global Partnership by unveiling a comprehensive roadmap…